{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T23:49:11Z","timestamp":1794354551271,"version":"4.9.0"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"20","license":[{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,5,16]]},"abstract":"<jats:sec>\n                    <jats:title>Rationale:<\/jats:title>\n                    <jats:p>Discoid lupus erythematosus (DLE) is a chronic, refractory condition causing visible scarring and significant psychological distress. Standard treatments often fail to provide adequate relief, necessitating new therapeutic options.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient concerns:<\/jats:title>\n                    <jats:p>A 43-year-old woman with longstanding DLE experienced recurrent scalp lesions unresponsive to multiple therapies, including high-dose corticosteroids, which caused adverse effects. A 19-year-old woman with systemic lupus erythematosus presented with persistent discoid scalp lesions, disfigurement, and emotional distress despite standard treatments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diagnoses:<\/jats:title>\n                    <jats:p>Both patients were diagnosed with refractory DLE, confirmed by clinical findings and skin biopsies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions and outcomes:<\/jats:title>\n                    <jats:p>Both patients received monthly intravenous anifrolumab (300\u2009mg) alongside hydroxychloroquine and methotrexate. Significant improvement was noted after the first dose, including reduced lesion severity, erythema, and itchiness, with visible hair regrowth. The first patient Cutaneous Lupus Erythematosus Disease Area and Severity Index-Activity score improved from 18 to 3, allowing complete corticosteroid discontinuation. The second patient Cutaneous Lupus Erythematosus Disease Area and Severity Index-Activity score decreased from 8 to 1. No adverse effects were reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lessons:<\/jats:title>\n                    <jats:p>These cases demonstrate anifrolumab potential as a treatment for refractory DLE, offering rapid and sustained improvement in disease severity and quality of life while reducing corticosteroid dependency. These findings suggest anifrolumab as a viable alternative for challenging DLE cases, warranting further research to confirm its efficacy and safety in larger populations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000042518","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T14:01:47Z","timestamp":1747836107000},"page":"e42518","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Anifrolumab for refractory discoid lupus: Two case reports of successful outcomes in Saudi Arabia"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3201-1308","authenticated-orcid":false,"given":"Roaa","family":"Aljohani","sequence":"first","affiliation":[{"name":"Department of Medicine, College of Medicine, Taibah University, Medina, Saudi Arabia"},{"name":"Department of Medicine, King Faisal Specialist Hospital and Research Centre, Medina, Saudi Arabia."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260811","doi-asserted-by":"crossref","first-page":"941003","DOI":"10.3389\/fmed.2022.941003","article-title":"An update on the management of refractory cutaneous lupus erythematosus.","volume":"9","author":"Verdelli","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"R2-20260811","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/art.39962","article-title":"Anifrolumab, an anti\u2013interferon\u2010\u03b1 receptor monoclonal antibody, in moderate\u2010to\u2010severe systemic lupus erythematosus.","volume":"69","author":"Furie","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"R3-20260811","doi-asserted-by":"crossref","first-page":"e208","DOI":"10.1016\/S2665-9913(19)30076-1","article-title":"Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial.","volume":"1","author":"Furie","year":"2019","journal-title":"Lancet Rheumatol"},{"key":"R4-20260811","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of anifrolumab in active systemic lupus erythematosus.","volume":"382","author":"Morand","year":"2020","journal-title":"N Engl J Med"},{"key":"R5-20260811","doi-asserted-by":"crossref","first-page":"e282","DOI":"10.1016\/S2665-9913(21)00317-9","article-title":"Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trials.","volume":"4","author":"Morand","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"R6-20260811","doi-asserted-by":"crossref","first-page":"e001007","DOI":"10.1136\/lupus-2023-001007","article-title":"Case series of anifrolumab for treatment of cutaneous lupus erythematosus and lupus-related mucocutaneous manifestations in patients with SLE.","volume":"10","author":"Bao","year":"2023","journal-title":"Lupus Sci Med"},{"key":"R7-20260811","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/mrcr\/rxae018","article-title":"Efficacy of anifrolumab in long-term intractable alopecia due to discoid lupus erythematosus.","volume":"8","author":"Azuma","year":"2024","journal-title":"Mod Rheumatol Case Rep"},{"key":"R8-20260811","doi-asserted-by":"crossref","first-page":"e2338200","DOI":"10.1001\/jamanetworkopen.2023.38200","article-title":"Anifrolumab for adolescent discoid lupus erythematosus.","volume":"6","author":"Shaw","year":"2023","journal-title":"JAMA Netw Open"},{"key":"R9-20260811","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jdcr.2023.04.024","article-title":"Successful treatment of severe chronic cutaneous lupus with anifrolumab: a series of 6 cases.","volume":"37","author":"Kowalski","year":"2023","journal-title":"JAAD Case Rep"},{"key":"R10-20260811","doi-asserted-by":"crossref","first-page":"e098","DOI":"10.1097\/JW9.0000000000000098","article-title":"Alopecia secondary to severe discoid lupus responding to anifrolumab.","volume":"9","author":"Han","year":"2023","journal-title":"Int J Womens Dermatol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000042518","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T08:01:01Z","timestamp":1786435261000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000042518"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,16]]},"references-count":10,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000042518","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,16]]}}}